Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal in Children with Fabry Disease
NCT00071877Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Oct 2003
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of agalsidase alfa in Fabry disease (FD), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoints: Safety of multiple biweekly intravenous doses of Replagal at 26 weeks and Pharmacokinetics of Replagal at 26 weeks. Started Oct 2003; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00071877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071877.